Publisher's Synopsis
The first comprehensive, definitive, and detailed overview of the preclinical and clinical development of the class of glycoprotein IIb/IIIa receptor antagonists. Written by the scientists who discovered and characterized this class of receptors, invented the first IIb/IIIa agents, and conducted the definitive clinical trials, this book elucidates the theoretical basis for the inhibition of platelet aggregation in the treatment of coronary syndromes, presents and synthesizes evidence for the efficacy of glycoprotein IIb/IIIa blockade in inhibiting ischemic complication of coronary intervention and acute coronary syndromes, and provides guidelines for the use of this novel class of agents in the clinical management of cardiovascular disease. Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease offers today's physicians and basic scientists the most complete and authoritative review available of the state-of-the-art in glycoprotein IIb/IIIa receptor inhibitor use.
